LinkedIn Profile

Access HμREL historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:hmrel 222529 May 28th, 2019 12:00AM Hurel Corp 217 8.00 Open Biotechnology May 28th, 2019 07:36PM May 28th, 2019 07:36PM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµRELViral™ - Long-enduring infectious liver disease model. Model is ready for viral infections of HBV, Malaria, and other lover specific diseases. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. Open hepatocytes, co-cultures, cell cultures, 3D cultures, in vitro toxicity, ADME, drug metabolism, Contract research, drug discovery, microfluidics, diagnostic microfluidic tools, organs-on-chip, organs under flow, organ-on-chip, IVIVC Open HµREL Corporation, 671 US Highway 1 Suite A NJ US 08902 HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 17th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 16th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 15th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 14th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 13th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 12th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 11th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 10th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology
private:hmrel 222529 Feb 9th, 2018 12:00AM Hurel Corp 171 16.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA. HμREL Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.